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LETTER TO THE EDITOR
Potential Cost-Effectiveness
of US-Guided FNAC
in Melanoma Patients
as a Primary Procedure
and in Follow-Up
TO THE EDITORS:
We read with great interest the vivid correspondence
between the authors of recent papers in the Annals of
Surgical.
1–3 The discussion focuses on a possible survival
beneﬁt for patients treated by sentinel lymph node biopsy
(SNLB) procedure compared with observation (OBS) and
the potential cost-effectiveness of SNLB in the light of
such a supposed survival beneﬁt, based on the third interim
results of the prospective Multicenter Selective Lymphad-
enectomy Trial-1 (MSLT-1).
4
Interestingly, the discussion also focuses on the nodal
relapse rates for both arms of the MSLT-1 trail (Table 1).
Strikingly, there seems to be an increase in late relapses in
both arms, which might either be the result of selection
bias, as follow-up has not yet matured to 10 years in the
entire MSLT-1 population and thus might lead to an
overestimation of the data, or these continuous late relapses
in both arms may indicate a failure rate of completion
lymph node dissection (CLND) completeness. Interestingly
we did not see any late relapses in our submicrometastases
(\0.1 mm) patients.
5–7
In light of the lack of survival beneﬁt for the sentinel
node (SN) procedure from the point of randomization in
the MSLT-1 trial, the cost-effectiveness of the SN proce-
dure as a staging procedure is debatable. Recently a study
by Voit et al. demonstrated that presurgical ultrasound
(US)-guided ﬁne-needle aspiration cytology (FNAC) has a
sensitivity of 65% compared with surgical SN procedure.
8
Moreover, the sensitivity of US-guided FNAC increases
signiﬁcantly with increasing SN tumor burden.
8
Considering that only 15–30% of all stage I/II melanoma
patients are SN positive, 70– 85% are negative but still
undergo a SN procedure.
4 US-guided FNAC has the poten-
tial to save 65–80% of SN-positive patients a SN staging
procedure and to save an estimated 61–92% of SN-negative
patients a surgical procedure, and the accompanying costs.
Here we would like to submit the argument for ultra-
sound-guided FNAC as a cost-effective alternative scenario
to the surgical SN procedure. For the purpose of these
calculations, based on the data by Voit et al., we considered
that 40% will undergo an US with FNAC whereas 60% will
have a benign US and will not undergo a FNAC.
8 More-
over, 50% will be FNAC positive and 50% will be FNAC
negative. Finally, the negative patients will undergo routine
US follow-up (four times a year), with an average of one
FNAC.
At our centers in The Netherlands and Germany, an SN
procedure and 1 day of hospital stay would cost an average
of €1254.83. Thus, for a scenario of 100 stage I/II mela-
noma patients, the total cost would be €125,483. Moreover,
these calculations do not take into account the time spent in
the operating theatre, which could be used for other
patients, and the strain on the waiting list for operations.
For the US-guided FNAC scenario, an average ultrasound
exam would cost €58.99 (without FNAC) and a US-guided
FNAC would cost an average of €168.61 at our centers. Fig-
ure 1showstheﬂowchartofUS-guided-FNACandthesumof
the costs. Total costs of US-guided FNAC as an alternative
would be €10,283.80 ? €45,831.40 = €56,115.20. This is
considerablylowerthanthe €125,483for100SNprocedures,
corresponding to a cost reduction of 55%.
In reality the savings will be higher as ultrasound is
increasingly used for the follow-up of melanoma patients,
evenafteranegativeSNorafteraCLNDforapositiveSN.At
present, these patients undergo in an increasing number of
centers an ultrasound exam twice a year for 5–10 years. This
wouldleadtocosts upto2 9 5 9 100 9 €58.99 = €58,990
(without any FNAC over the entire follow-up period). Thus
the potential saving might even be much higher, approxi-
mately 70%.
Thus, US-guided FNAC emerges as an alternative and
cost-effective staging procedure compared with surgical SN,
with the potential to save up to €69,367.80 ([50%) at our
centers, plus the obvious beneﬁts such as saving patients
unnecessary surgery, morbidity, operation theatre time, and
reducingthestrainonthewaitinglistforoperations.Therefore
there isa needtoreproduce the results fromthe study by Voit
et al. to establish the value of US-guided FNAC.
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FIG. 1 Cost-effectiveness ﬂowchart
of ultrasound-guided FNAC
TABLE 1 Nodal metastasis rate and rate of increase according to time for sentinel node (SN) and observation (OBS) arms of the Multicenter
Selective Lymphadenectomy Trial-1 (MSLT-1)
SN arm Increase OBS arm Increase Difference
0 years 15.6% 15.6% 0% 100%
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7 years 19.6% (± 1.5%) 0.2% 0.1%/year 17.0% (± 1.7%) 0.9% 0.45%/year 2.6%
10 years 20.8% 1.2% 0.4%/year 20.5% 3.5% 1.2%/year 0.3%
From: Morton, 6th Biannual International Sentinel Node Society meeting, Sydney 2008
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